Search

Displaying results 1301 - 1310 of 1786 in total
  1. Drug

    Glycyrrhizic acid

    go.drugbank.com/drugs/DB13751
    ApprovedInvestigational

    [A33062] From January 2014, glycyrrhizic acid as part of the licorice extract was approved by the FDA as an existing food sweetener.

  2. Drug

    Risdiplam

    go.drugbank.com/drugs/DB15305
    ApprovedInvestigational

    [L15351,A216871] Risdiplam was approved by the FDA in August 2020 for the treatment of spinal muscular atrophy (SMA).

  3. Drug

    Nedosiran

    go.drugbank.com/drugs/DB17635
    ApprovedInvestigational

    [A261685] Nedosiran was approved by the FDA on October 2<sup>nd</sup>, 2023, under the brand name RIVFLOZA to lower urinary oxalate levels in children 9 years of age and older and adults with primary

  4. Drug

    Metoclopramide

    go.drugbank.com/drugs/DB01233
    ApprovedInvestigational

    [T683] Metoclopramide was initially approved by the FDA in 1980.[A184922]

  5. Drug

    Lasofoxifene

    go.drugbank.com/drugs/DB06202
    ApprovedInvestigationalWithdrawn

    It was initially developed as Oporia by Pfizer as a treatment for postmenopausal osteoporosis and vaginal atrophy, in which were both rejected for approval by FDA.

  6. Drug

    Nalmefene

    go.drugbank.com/drugs/DB06230
    ApprovedInvestigationalWithdrawn

    [L40684] The nasal spray formulation of nalmefene was approved by the FDA in May 2023.[L46511]

  7. Drug

    Olipudase alfa

    go.drugbank.com/drugs/DB12835
    ApprovedInvestigational

    [A251590] It was later approved by the European Commission on June 28, 2022 [L42740] and by the FDA on August 31, 2022.[L43145]

  8. Drug

    Ensulizole

    go.drugbank.com/drugs/DB11115
    Approved

    According to the FDA, the maximal approved concentration of ensulizole is 148 mM although concentrations ranging between 74 and 148mM can be found in commercial sunscreen products [A27151].

  9. Drug

    Ceftazidime

    go.drugbank.com/drugs/DB00438
    ApprovedInvestigational

    [L32935] Ceftazidime was approved by the FDA on July 19, 1985, and is currently available either alone or in combination with the non-β-lactam β-lactamase inhibitor [avibactam] to treat a variety of

  10. Drug

    Tirbanibulin

    go.drugbank.com/drugs/DB06137
    ApprovedInvestigational

    [A225726] On December 14, 2020, tirbanibulin was approved by the FDA for the topical treatment of actinic keratosis on the face or scalp. It is marketed under the brand name Klisyri.